Martin Thomas J, Martin Conner W, Frankowski Kevin J, Blough Bruce E, Aubé Jeffrey, Bohn Laura M, Jones Sara R
Pain Mechanisms Lab, Department of Anesthesiology, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA.
UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Psychopharmacology (Berl). 2025 May 6. doi: 10.1007/s00213-025-06800-3.
Numerous pharmacological classes of compounds have been explored as novel and efficacious alternatives to standard mu opioid agonist analgesics. We and others have described G-protein biased kappa opioid agonists as having potential utility as analgesics due to a lower propensity to produce sedation and dysphoria, which are thought to be mediated in large part through beta-arrestin signaling.
Here we compare two G-protein biased kappa agonists that differ in their basic chemical scaffold, triazole 1.1 (Tr1.1) and isoquinolinone 2.1 (Iso2.1), for alteration of intracranial self-stimulation (ICSS) in male and female rats. Lactic acid (LA) was given i.p. at a concentration sufficient to produce moderate to severe depression of ICSS.
Neither Tr1.1 nor Iso2.2 reversed the effects of lactic acid at concentrations that produced significant depression of ICSS in either sex. Neither drug altered ICSS in the absence of lactic acid administration. In both males and females, morphine reversed the effects of i.p. lactic acid on ICSS and co-administration of Tr1.1 did not alter the dose-effect curve for morphine in either sex. Similar effects were observed for ketoprofen. Ketoprofen also reversed the effects of i.p. lactic acid on ICSS in both sexes in a dose-dependent manner, and co-administration of neither Tr1.1 nor Iso2.1 altered the ketoprofen dose-effect curve.
These data suggest that these G-protein biased kappa agonists may lack sufficient efficacy or potency to alter the effects of opioids or NSAIDs against moderate to severe antinociceptive stimuli in rats, and development of more potent or efficacious compounds may be required to demonstrate efficacy in rat models of moderate to severe nociception.
人们已经探索了多种药理类化合物,作为标准μ阿片受体激动剂镇痛药的新型有效替代品。我们和其他人已经描述了G蛋白偏向性κ阿片受体激动剂具有作为镇痛药的潜在效用,因为它们产生镇静和烦躁不安的倾向较低,而这些作用在很大程度上被认为是通过β-抑制蛋白信号传导介导的。
在此,我们比较了两种基本化学结构不同的G蛋白偏向性κ激动剂,三唑1.1(Tr1.1)和异喹啉酮2.1(Iso2.1),对雄性和雌性大鼠颅内自我刺激(ICSS)的影响。腹腔注射乳酸(LA),其浓度足以使ICSS产生中度至重度抑制。
在使两性ICSS产生显著抑制的浓度下,Tr1.1和Iso2.2均未逆转乳酸的作用。在未给予乳酸的情况下,两种药物均未改变ICSS。在雄性和雌性大鼠中,吗啡均能逆转腹腔注射乳酸对ICSS的作用,并且Tr1.1的共同给药并未改变两性中吗啡的剂量-效应曲线。酮洛芬也有类似的作用。酮洛芬也以剂量依赖性方式逆转了腹腔注射乳酸对两性ICSS的作用,并且Tr1.1和Iso2.1的共同给药均未改变酮洛芬的剂量-效应曲线。
这些数据表明,这些G蛋白偏向性κ激动剂可能缺乏足够的效力或效能来改变阿片类药物或非甾体抗炎药对大鼠中度至重度抗伤害性刺激的作用,可能需要开发更有效或更高效的化合物,以在中度至重度伤害感受的大鼠模型中证明其疗效。